| Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the … DC Wheeler, BV Stefánsson, N Jongs, GM Chertow, T Greene, FF Hou, ... The lancet Diabetes & endocrinology 9 (1), 22-31, 2021 | 480* | 2021 |
| A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy DC Wheeler, RD Toto, BV Stefansson, N Jongs, GM Chertow, T Greene, ... Kidney international 100 (1), 215-224, 2021 | 298 | 2021 |
| Effects of dapagliflozin in stage 4 chronic kidney disease GM Chertow, P Vart, N Jongs, RD Toto, JL Gorriz, FF Hou, JJV McMurray, ... Journal of the American Society of Nephrology 32 (9), 2352-2361, 2021 | 197 | 2021 |
| Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial N Jongs, T Greene, GM Chertow, JJV McMurray, AM Langkilde, ... The lancet Diabetes & endocrinology 9 (11), 755-766, 2021 | 155 | 2021 |
| Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the … HJL Heerspink, N Jongs, GM Chertow, AM Langkilde, JJV McMurray, ... The lancet Diabetes & endocrinology 9 (11), 743-754, 2021 | 150 | 2021 |
| Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs, D Postmus, ... Circulation 143 (5), 438-448, 2021 | 142* | 2021 |
| Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial M Provenzano, MJ Puchades, C Garofalo, N Jongs, L D’Marco, ... Journal of the American Society of Nephrology 33 (8), 1569-1580, 2022 | 118 | 2022 |
| Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial HJL Heerspink, CD Sjöström, N Jongs, GM Chertow, M Kosiborod, ... European heart journal 42 (13), 1216-1227, 2021 | 100 | 2021 |
| Effects of dapagliflozin in patients with kidney disease, with and without heart failure JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs, D Postmus, ... Heart Failure 9 (11), 807-820, 2021 | 99 | 2021 |
| Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in … DC Wheeler, N Jongs, BV Stefansson, GM Chertow, T Greene, FF Hou, ... Nephrology Dialysis Transplantation 37 (9), 1647-1656, 2022 | 80 | 2022 |
| Efficacy and safety of dapagliflozin by baseline glycemic status: A prespecified analysis from the DAPA-CKD trial F Persson, P Rossing, P Vart, GM Chertow, FF Hou, N Jongs, ... Diabetes care 44 (8), 1894-1897, 2021 | 78 | 2021 |
| Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials P Rossing, SE Inzucchi, P Vart, N Jongs, KF Docherty, PS Jhund, L Køber, ... The Lancet Diabetes & Endocrinology 10 (1), 24-34, 2022 | 70 | 2022 |
| Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial SW Waijer, P Vart, DZI Cherney, GM Chertow, N Jongs, AM Langkilde, ... Diabetologia 65 (7), 1085-1097, 2022 | 62 | 2022 |
| The kidney protective effects of the sodium–glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists M Provenzano, N Jongs, P Vart, BV Stefánsson, GM Chertow, ... Kidney international reports 7 (3), 436-443, 2022 | 57 | 2022 |
| DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients … DC Wheeler, RD Toto, BV Stefánsson, N Jongs, GM Chertow, T Greene, ... Kidney Int 100 (1), 215-224, 2021 | 53 | 2021 |
| Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD N Jongs, GM Chertow, T Greene, JJV McMurray, AM Langkilde, ... Journal of the American Society of Nephrology 33 (11), 2094-2107, 2022 | 46 | 2022 |
| Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes P Vart, M Vaduganathan, N Jongs, G Remuzzi, DC Wheeler, FF Hou, ... Clinical Journal of the American Society of Nephrology 17 (12), 1754-1762, 2022 | 45 | 2022 |
| A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data N Jongs, R Jagesar, NEM van Haren, BWJH Penninx, L Reus, PJ Visser, ... Translational psychiatry 10 (1), 211, 2020 | 44 | 2020 |
| Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials EM Apperloo, BL Neuen, RA Fletcher, N Jongs, SD Anker, DL Bhatt, ... The Lancet Diabetes & Endocrinology 12 (8), 545-557, 2024 | 38 | 2024 |
| DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a … N Jongs, T Greene, GM Chertow, JJV McMurray, AM Langkilde, ... Lancet Diabetes Endocrinol 9 (11), 755-766, 2021 | 31 | 2021 |
Hiddo Lambers HeerspinkUniversity of GroningenBestätigte E-Mail-Adresse bei umcg.nl